Lilly’s orforglipron cut body weight as expected in the Phase III ATTAIN-1 trial, but to a lesser extent than rival Novo ...

Eli Lilly shares fell after orforglipron's Phase 3 data showed less weight loss than rival drugs, despite a strong Q2 ...

Lilly's daily obesity pill, orforglipron, shows positive results in late-stage trial, with patients losing nearly 12% of body ...

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...

For comparison, Lilly's arch-rival in the weight-loss category, Novo Nordisk, is developing an oral formulation of ...

Shock’ as study reveals how weight-loss pill stacks up against injections - Shares in a pharmaceutical company plummeted ...

A trial assessing a new daily pill for weight loss has shown that people taking the drug can shed kilos in weeks, potentially ...

According to Chamelin’s grant application, the church plans to spend $1,500 to buy the livestock, $375 to butcher, process ...

At the same time, Trump's hint of a carveout for coming duties on semiconductors boosted tech for a second consecutive day.

Investing.com -- Viking Therapeutics (NASDAQ: VKTX) stock rose 11% Thursday after Eli Lilly’s (NYSE: LLY) data on its oral ...

Stocks are rising on Wall Street, even as President Donald Trump’s latest tariffs kicked into effect on dozens of countries ...

Eli Lilly's Q2 earnings soared, fueled by Mounjaro and Zepbound's impressive sales, leading to raised full-year guidance.